Antiretroviral therapy for previously untreated HIV-1-infected adults: 2NN, or just one?

Lancet

Volumn 363, Issue 9417, 2004, Pages 1248-1250

  Carr, Andrew ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; EFAVIRENZ; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CENTRAL NERVOUS STIMULATION SYNDROME; CLINICAL TRIAL; DIARRHEA; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG RESEARCH; FEVER; GASTROINTESTINAL TOXICITY; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LIPODYSTROPHY; LIVER TOXICITY; METABOLIC DISORDER; MUCOSA INFLAMMATION; NAUSEA; NOTE; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; PRIORITY JOURNAL; RASH; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SUICIDE ATTEMPT; TREATMENT OUTCOME;

EID: 1942471103     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16028-5     Document Type: Note

References (16)

1. Stas0zewski S., Morales-Ramirez J., Tashima K.T., et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 341:1999;1865-1873.
2. Staszewski S., Keiser P., Montaner J., et al. Abacavir-lamivudine- zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. JAMA. 285:2001;1155-1163.
3. Podzamczer D., Ferrer E., Consiglio E., et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antivir Ther. 7:2002;81-90.
4. Nunez M., Soriano V., Martin-Carbonero L., et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals. HIV Clin Trials. 3:2002;186-194.
5. van Leeuwen R., Katlama C., Murphy R.L., et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS. 17:2003;987-999.
6. Robbins G.K., De Gruttola V., Shafer R.W., et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 349:2003;2293-2303.
7. Bartlett JA, Johnson J, Herrera G, Sosa N, Rodriguez AE, Shaefer MS. Abacavir/lamivudine in combination with efavirenz, amprenavir/ritonavir or stavudine: ESS40001 (CLASS) preliminary 48 week results. 14th International AIDS Conference, Barcelona, July, 2002: TuOrB1189 (abstr).
8. Montaner J, Saag M, Barylski C, Siemon-Hryczyk P. FOCUS study: week 24 results. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, December, 2001: H-670 (abstr).
9. Delfraissy JF, Rivero A, Yakovlev A, for the A1424-034 International Study Team. Comparison of antiretroviral efficacy and safety of atazanavir QD and efavirenz QD with fixed dose ZDV+3TC - AI424-034. 6th International Congress on Drug Therapy in HIV, Glasgow, UK, November, 2002: P36 (abstr).
10. Gallant JE, Rodriguea AE, Weinberg W, et al. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz + ABC and 3TC: ESS30009 unplanned interim analysis. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, September, 2003: H-1722a (abstr).
11. Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health. Important interim results from a phase III, randomized, double-blind comparison of three protease-inhibitor-sparing regimens for the initial treatment of HIV infection (AACTG Protocol A5095). http://aactg.s-3.com/pub/download/a5095v2info-310.pdf (accessed Feb 26, 2004).
12. Panel on Clinical Practices for Treatment of HIV Infection, Department of Health and Human Services (DHHS) and the Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://aidsinfo.nih.gov/guidelines/default_db2.asp?id=50 (accessed Feb 27, 2004).
13. Fellay J, Boubaker K, Lederberger B, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001; 358: 1322-27.
14. Chene G., Sterne J.A., May M., et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet. 362:2003;679-686.
15. Hall D, van Leth F, Schere J, et al. Genotypic analysis of reverse transcriptase in treatment-naïve HIV-1 patients treated with lamivudine, stavudine and nevirapine and/or efavirenz. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, USA, February, 2004: 694 (abstr).
16. National Cholesterol Education Program. Risk assessment tool for estimating your 10-year risk of having a heart attack. http://hin.nhlbi.nih.gov/ atpiii/calculator.asp (accessed March 2, 2004).